Bridging Tumor Genomics to Patient Outcomes Through an Integrated Patient-Derived Xenograft Platform
David R. Gandara(University of California, Davis), Edison T. Liu(Jackson Laboratory), Chong-xian Pan(VA Northern California Health Care System), Rebekah A. Burich(UC Davis Comprehensive Cancer Center), Carol J. Bult(Whitehead Institute for Biomedical Research), James Keck(Jackson Laboratory), Stephanie H. Astrow, Regina Gandour‐Edwards(University of California, Davis), Susan Airhart(The University of Texas MD Anderson Cancer Center), Primo N. Lara(UC Davis Comprehensive Cancer Center), David T. Cooke(University of California Davis Medical Center), Tianhong Li(VA Northern California Health Care System), Neal Goodwin(Champions Oncology (United States)), Jonathan W. Riess(University of California Davis Medical Center), Ken Y. Yoneda(University of California Davis Medical Center), Elizabeth Hernández Moore(Harvard University), Ralph W. de Vere White(UC Davis Comprehensive Cancer Center), Elizabeth A. David(Grant Medical Center), Philip C. Mack(UC Davis Comprehensive Cancer Center)
Cited by 19
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k